Sodium reduction is efficacious for primary prevention of hypertension, but the feasibility of achieving this effect is unclear. The objective of the paper is detailed analyses of adherence to and effects of the sodium reduction intervention among overweight adults in the Trials of Hypertension Prevention, Phase II. Sodium reduction (comprehensive education and counselling about how to reduce sodium intake) was tested vs no dietary intervention (usual care) for 36-48 months. A total of 956 white and 203 black adults, ages 30-54 years, with diastolic blood pressure 83-89 mmHg, systolic blood pressure (SBP) o140 mmHg, and body weight 110-165% of gender-specific standard weight were included in the study. At 36 months, urinary sodium excretion was 40.4 mmol/24 h (24.4%) lower in sodium reduction compared to usual care participants (Po0.0001), but only 21% of sodium reduction participants achieved the targeted level of sodium excretion below 80 mmol/24 h. Adherence was positively related to attendance at face-to-face contacts. Net decreases in SBP at 6, 18, and 36 months of 2.9 (Po0.001), 2.0 (Po0.001), and 1.3 (P ¼ 0.02) mmHg in sodium reduction vs usual care were associated with an overall 18% lower incidence of hypertension (P ¼ 0.048); were relatively unchanged by adjustment for ethnicity, gender, age, and baseline blood pressure, BMI, and sodium excretion; and were observed in both black and white men and women. From these beneficial but modest results with highly motivated and extensively counselled individuals, sodium reduction sufficient to favourably influence the population blood pressure distribution will be difficult to achieve without food supply changes.
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Introduction
The benefits of sodium reduction for blood pressure (BP) control have been well documented in individuals with established hypertension [1] [2] [3] [4] [5] and also in individuals at risk of developing hypertension. [6] [7] [8] In particular, Phase I of the Trials of Hypertension Prevention (TOHP I) 9 demonstrated a significant effect of sodium reduction in reducing the average BP of 30-54-year-old men and women who were not hypertensive but whose diastolic BP (DBP) was initially in the high normal range (between 80 and 89 mmHg). The approximately 30% reduction in 24-h urinary sodium excretion in the sodium intervention group over 18 months of follow-up 10 was associated with a net reduction in average systolic BP (SBP) and DBP, respectively, of 2 and 1 mmHg.
Although not statistically significant, the net reduction in the occurrence of new cases of hypertension was 26%. A second phase of TOHP (TOHP II) studied the efficacy of sodium reduction for hypertension prevention in overweight adults in the same age range for a longer period (36-48 months) than in TOHP I. 11 TOHP II included only men and women who were at least moderately overweight in order to evaluate, in a factorial design, the effects of weight reduction as well. 12 As reported previously, 11 sodium reduction was associated with a significantly lower incidence of hypertension and statistically significant BP reductions in TOHP II participants, but with attenuation of effects over time. We have examined the TOHP II sodium intervention results in detail with respect to adherence, treatment effects, and dose response, including exploration of results by ethnicity, gender, and genotype at the angiotensinogen locus. The dose response of blood pressure change per unit sodium intake change is addressed in a separate paper. 13 
Materials and methods

Study design
TOHP II was a multicentre, randomized controlled clinical trial in which moderately overweight individuals were assigned equally to one of four conditions in a factorial design: weight loss alone, sodium reduction alone, the combination of weight reduction and sodium reduction, or a usual care control involving no study-delivered intervention, 11, 12 for 36-48 months. The nine TOHP II clinical centres were located in diverse regions of the United States: Baltimore, MD; Birmingham, AL; Davis, CA; Jackson, MS; Memphis, TN; Newark, NJ; Portland, OR; Pittsburgh, PA; and St. Louis, MO. A coordinating centre, located in Boston, MA, and the National Heart, Lung, and Blood Institute project office (Bethesda, MD) also participated. Outcome variables were change in DBP from baseline to the final visit (primary outcome), change in SBP, and incidence of hypertension (secondary outcomes). Hypertension was defined as DBP X90 mmHg, SBP X140 mmHg, or self-reported diagnosis of hypertension with drug treatment. Statistical assumptions for the planned sample size of 2250 have been reported. 12 Potentially eligible participants were healthy men and women aged 30-54 years, who were approximately 110-165% of the Metropolitan Life Insurance Company 14 weight standards. Blood pressure eligibility criteria were: DBP between 83 and 89 and SBP o140 mmHg when nine readings taken over three visits were averaged. Exclusions were: current treatment for hypertension; evidence of cardiovascular disease, diabetes mellitus, renal insufficiency, or other serious illness; current or planned pregnancy; or unwillingness or inability to adhere to trial procedures.
Sodium reduction program
A description of the design considerations, structure, and format of the TOHP II sodium intervention has been published. 15 The general strategy was to provide participants with the knowledge and skills needed to reduce their sodium intake through intensive initial counselling, with subsequent counselling on a less frequent basis to prevent relapse and support maintenance of sodium reduction (see Table 1 ). Participants were expected to make targeted changes in their usual food selections and eating patterns to lower sodium intake without affecting caloric intake or other aspects of dietary intake or lifestyle. The intervention was delivered by registered dietitians or other nutrition counsellors, with support from behavioural psychologists as co-leaders or consultants. The intervention protocol (eg, content, contact pattern, and frequency of group sessions) was the same at all the nine centres and was not specifically tailored for gender or ethnicity. Supplemental individual contacts and booster sessions were offered to improve adherence during the extended phase as feasible and deemed necessary by the intervention staff. Intervention staff were centrally trained initially, with continuing support and monitoring by the study coordinating centre. Adherence measures such as food diaries and overnight urine samples were not used as study outcome data.
Data collection
Study procedures were approved by the institutional review boards of the participating centres, and informed consent was obtained from all participants at the time of screening and randomization. At each clinic, the same specially trained staff collected data from both sodium reduction and usual care participants on a set schedule, using standardized trial-wide equipment and procedures. 12 By protocol, data collection staff were different from intervention staff and were kept unaware of the participant's randomization group. Baseline data were collected over a series of three visits spaced 7-45 days apart. Follow-up data collection visits were every 6 months after randomization for at least 36 months, and up to 48 months for participants randomized early in the study. BP (three readings per visit), body weight, and reported use of medications were recorded at each follow-up visit. At three time points (baseline, 18, and 36 months) BP was measured in the sitting position over three visits approximately 1 week apart, with a single visit at other times. Dietary data were collected at 18 and 36 months from a subsample of randomly selected participants with equal represen-tation across each of the four conditions (single 24-h recall from 900 and 3-day food records from 150).
The primary measure of sodium intake was sodium excretion in 24-h urine samples. Participants were asked to submit 24-h urinary sodium specimens at baseline, that is, during the series of screening and randomization visits (all participants), at the 6-month visit (approximate 25% random subsample of participants across all conditions), and at the 18-and 36-month visits (all participants). Validity of urine samples was determined from volume (X500 g by weight) and reported duration (between 18 and 36 h). Urine samples were also analysed for creatinine and potassium. For sodium reduction participants, 7, 5, 21, and 5 urines were excluded at baseline, 6, 18, and 36 months, respectively; the comparable numbers excluded for usual care were 12, 4, 13, and 6. Urinary creatinine excretion was calculated, but because of the inherent variability in this measure, was not used to discard or adjust individual excretion data.
Baseline urinary sodium excretion data were obtained from 97% of randomized participants; urine collections were obtained from 22% of randomized participants (subsample) at 6 months and from 79 and 81% at the 18-and 36-month follow-ups, respectively. At baseline, collections were submitted by 96.5 and 92.3%, respectively, of black men and women compared to 97.8 and 98.2% of white men and women (w 2 analysis; P ¼ 0.006). At 18 months, collections were submitted by 73 and 71% of black men and women compared to 80 and 79% of white men and women (P ¼ 0.078). At 36 months, collections were submitted by 74% of both black men and women, compared to 83% of both white men and women (P ¼ 0.038).
Genotyping
A TOHP II substudy provided for genotyping at two loci of the angiotensin gene that have been associated with increased transcription and resulting increased circulating levels of angiotensinogen, as well as increased BP level and its response to lifestyle intervention. 16, 17 To obtain white cells for genotyping, blood was drawn at the 36-month or end-of-study visits from all consenting participants who had a clinic visit after the substudy began. Assays were performed by Myriad Genetics, Inc, in Salt Lake City, UT, as described elsewhere. 16 Genotypes were determined at two highly concordant loci of the angiotensinogen gene on chromosome 1: at amino acid 235 coded for in exon 2 and at position À6 in the promoter region. Results are reported for the latter of these two loci. A substitution of G for A at this locus is associated with higher angiotensinogen levels.
Statistical analyses
Baseline characteristics of those assigned to sodium reduction and usual care were compared by gender and by ethnicity (black vs white) using t-tests for means, and w 2 tests for proportions. Level and changes from baseline in excretion values were compared between the sodium reduction and usual How to identify Na content of foods, prepare lower Na foods, modify recipes, and make lower Na food selections at and between meals and when eating away from home; taste-testing lower Na packaged foods and recipes; how to make small, progressive Na intake changes; alternatives to high-Na eating behaviours; general behavioural modification and relapse prevention techniques, including selfmonitoring of Na intake; counsellor and peer support Strategies used to enhance adherence Counsellor feedback based on submitted food records Individual and group feedback on changes in urinary Na excretion based on timed, overnight urine samples or 24-h urine samples Various reminders and incentives throughout follow-up Evaluation of participation Attendance at scheduled group and individual counselling sessions; frequency of telephone contacts Evaluation of adherence Na content of 24-h urine samples (and creatinine content, for completeness of collection) at 6, (25% subsample), 18, and 36 months care control group at each time point, and were tested using two-sample t-tests. A log transformation was used to estimate and test the percent change from baseline in sodium excretion. The geometric mean was computed, and the standard deviation was estimated using the delta method. This procedure was repeated among subgroups defined by gender and ethnicity. The percent attaining 24-h excretion levels below 80 mmol (the study goal) and below 100 mmol (the approximate sodium intake level recommended for the population at large 7, 8 ) among those in sodium reduction were calculated to estimate goal achievement. Predictors of such achievement were examined using logistic regression. Candidate variables included gender, ethnicity, education, employment, marital status, smoking, alcohol use, BMI, and attendance at intervention sessions. Models were first run separately for goal achievement at 18 and 36 months, and then for the average over both visits.
BP was measured at baseline and every 6 months as described above; for persons who started antihypertensive drug treatment, the last reading prior to use of medication was carried forward. Those placed on medications affecting BP for other reasons were treated as missing at that visit. Treatment effects on BP were first estimated using two-sample t-tests of change from baseline for both overall and within subgroups defined by ethnicity and gender. In addition, linear regression analysis was used to adjust for ethnicity, gender, age, education, and baseline BP, excretion values, and weight. Incidence of hypertension, defined as DBP X90 mmHg or SBP X140 mmHg or diagnosis and treatment with BPlowering medication, was compared using life-table methods. A prior analysis of TOHP II data for white participants identified differences in response to the sodium intervention according to subgroups defined by AGT genotype (larger diastolic blood pressure decrease in the AA genotype subgroup than in the GG group). 16 That analysis excluded blacks because of the very small sample size for African Americans with the GG genotype. 16 Here, we explored intervention effects by AGT genotype within each of the four ethnicity-gender subgroups. Adjusted net intervention effects on BP were estimated using linear regression, adjusting for age, baseline sodium and BP, and change in weight. In addition, since sodium change varied across ethnicity-gender groups, estimated treatment effects were standardized to an equal change in sodium excretion. Treatment effects were estimated at a sodium change equal to the net sodium reduction of 51.3 mmol in men and 19.8 mmol in women at 36 months.
Results
Participant characteristics
TOHP II randomized 2382 participants. These analyses include the 1159 black or white participants randomized to either sodium reduction alone (n ¼ 582) or usual care (n ¼ 577). As reported elsewhere, 18 randomization groups had similar baseline characteristics, except that participants randomized to sodium reduction were, on average, 1 year older than those randomized to usual care (44.2 vs 43.2 years). Randomization was not stratified on ethnicity or gender, but sodium reduction and usual care participants were also relatively comparable within ethnicity-gender groups.
In this analysis sample, approximately two-thirds of participants were male, about half were college graduates, and the majority were married and employed full time. Black participants were 17% of the total (n ¼ 203); the percent black differed between men (11%) and women (29%). Baseline characteristics for subgroups are in Table 2 . Women were older and less likely than men to be college graduates, to be married or employed fulltime, and to have ever smoked. In the subsample with dietary data, women reported lower calorie intakes, higher percent of calories from fat, and lower sodium, potassium, and calcium intakes. Gender differences for 24-h sodium and potassium excretion were in the same direction as the dietary data.
Compared to black men, white men had higher educational attainment, more were employed, and more were married. White men reported dietary intakes that were higher in calories, fat and saturated fat, lower in carbohydrate, and higher in sodium, potassium, and calcium (unadjusted for calories) compared to those of the black men. Compared to black women, white women were older, fewer were employed, and more were married, and the dietary intakes reported by the white women were lower in protein and higher in calories, potassium, and calcium. Urinary sodium-to-potassium (Na/K) ratio was lower in whites than blacks in both men and women, due primarily to the higher potassium excretion in whites.
Attendance
During the overall follow-up from baseline to 36-48 months, 90% of participants in sodium reduction had at least one face-to-face contact, and 56% had 9-11 such contacts. Attendance was highest during the first (most intensive) 6 months: 72.7% of sodium reduction participants attended at least half of the expected counselling sessions (see contact pattern in Table 1 ) between baseline and 6 months, whereas only 30.1 and 11.3% had this level of attendance between 6 and 18 months and 18 and 36 months, respectively. Attendance at group sessions was similar for men and women within ethnicity, but was lower for blacks than whites. For example, only 80% of black men and 77% of black women attended any group sessions, compared to 86% of white men and 87% of white women. Overall, 82% of black participants compared to 92% of white participants had at least one face-to-face contact (the initial individual contact is included), and approximately 40% of blacks compared to approximately 60% of whites had nine or more in-person contacts.
Sodium excretion
Mean change from baseline by randomization group Changes in urinary sodium excretion by intervention group are shown in Table 3 . For the total analysis sample, urinary sodium excretion decreased significantly in sodium reduction vs usual care participants at 6, 18, and 36 months, with the largest decrease at 6 months, the decrease from baseline at 18 months maintained at 36 months, and net decreases of 51, 43, and 40 mmol/24 h, respectively, at these three follow-up visits. Expressed as percent change from baseline to 36 months, the decrease in mean (s.d.) sodium excretion was 31.7(42.5) and 7.3 (48.6)%, respectively, in sodium reduction and usual care for a net decrease of 24.4% (95% CI ¼ 18.7, 30.2) (not shown).
The decrease in sodium excretion was larger for men than women (Table 3 ). In men, the mean (s.d.) percent change in sodium excretion at 36 months was À35.1 (39.9) and À5.8 (49.3), respectively for sodium reduction vs usual care, for a net decrease of 29.3% (95% CI ¼ 22.3, 36.2) (not shown). In women, the mean (s.d.) percent change in sodium excretion at 36 months was À25.1 (46.99) and À10.6 (46.9), respectively, for sodium reduction vs usual care, for a net decrease of 14.6% (95% CI ¼ 3.6, 25.7). Table 3 also demonstrates the relative consistency of intervention effects for blacks and whites, within gender, considering the small sample sizes for blacks, especially at 6 months.
Goal achievement in the sodium reduction group
The reductions in sodium excretion were not sufficient to attain the study design goal of an average excretion of o80 mmol/24 h. Mean (s.d.) When the sodium reduction data were examined at the individual level, baseline 24-h sodium excretion levels were equal to or above 100 mmol for 89% of participants and equal to or above the study goal of 80 mmol for 96%. At 6 months, 51% of participants had sodium excretion below 100 mmol, and 39% had sodium excretion below 80 mmol. Using the average of the 18-and 36-month excretion levels for each individual with data at both visits (n ¼ 534), the proportion attaining o100 mmol/24 h was about one-third overall-30% for white men, 36% for black men, 39% for white women, and 35% for black women. The proportion attaining o80 mmol/24 h was only 21% overall-19, 24, 25, and 20%, respectively, for white and black men, and white and black women.
Predictors of goal achievement
Better attendance at intervention sessions was associated with greater mean sodium reduction (Figure 1 ). Bivariate analyses suggested positive associations of goal achievement at 18 months or both 18 and 36 months, respectively, with attendance (o9 vs 9 þ total in-person contacts) (P ¼ 0.01. and 0.05), being female (P ¼ 0.009 and 0.02), being college educated (P ¼ 0.19 and 0.05), not smoking (P ¼ 0.8 and 0.05), and smaller body size (P ¼ 0.02 and 0.002). In the multivariate models, attendance was independently associated with goal achievement at 18 months (OR (95% CI) ¼ 1.8 (1.1, 2.9); P ¼ 0.015), but was not significant at 36 months (1.4 (0.9, 2.3); P ¼ 0.16). Being female was a significant independent predictor of goal achievement at both 18 months (OR (95% CI) ¼ 1.9 (1.1, 3.2); P ¼ 0.02) and 36 months (1.9 (1.1, 3.4); P ¼ 0.03). An inverse association with BMI was suggested at 18 months and was significant at 36 months, independent of the other model variables: OR ¼ 0.94 (0.87, 1.01); P ¼ 0.07 at 18 months; 0.90 (0.84, 0.98); P ¼ 0.01 at 36 months. Reporting current alcohol use at baseline also appeared to be directly associated with goal achievement at 36 months (OR ¼ 1.70 (1.0; 2.8); P ¼ 0.04).
Other changes
Dietary intake Some relatively small changes in dietary factors other than sodium were observed in the dietary data subsample. There were net decreases in kilocalories (36 months), total fat, saturated fat intake, and calcium intake at both 18 and 36 months, and vitamin C intake at 36 months (see Table 4 ). These effects were smaller but still present after adjusting for kilocalorie intake with linear regression, except calcium at 18 months, which changed from P ¼ 0.06 to P ¼ 0.18). In addition, a small increase in mean fibre intake was observed with adjustment for kilocalorie intake (net change 1.97 g (P ¼ 0.043) at 18 months and 1.44 g (P ¼ 0.13) at 36 months.
Potassium excretion and urinary sodium to potassium ratio Although participants were not counselled to change their potassium intake, changes in potassium excretion were examined to evaluate the possibility of spontaneous changes resulting from dietary modifications undertaken to reduce sodium intake (eg, substitution of fresh fruits and vegetables for high sodium snack foods). Potassium excretion showed generally small decreases in both sodium reduction and usual care participants, which were not statistically significant, either overall or within gender or ethnicity gender subgroups. The urinary Na/K ratio was also examined to assess the potential effects of simultaneous changes in sodium and potassium intake within individuals and because this ratio was included in some analyses of treatment effects. Similar to the pattern observed for sodium intake, and consistent with the relative lack of change in potassium excretion, this ratio decreased significantly in sodium reduction vs usual care participants at 6, 18, and 36 months, with the largest decrease at 6 months and relatively little change between 18 and 36 months. With sexes combined, urinary Na/K excretion in the sodium reduction group decreased from 3.1 at baseline to 1.9 at 6 months and was 2.4 and 2.5, respectively, at 18 and 36 months. In usual care, the urinary Na/K ratio was 3.1 at baseline, 3.0 at 6 months, and 3.2 at Figure 1 Change in urinary sodium excretion (mmol urinary sodium excretion per 24 h) by cumulative attendance at each time point. N is for sample with urine data at follow-up visit. Urine data at 6 months were collected for a randomly selected 25% subsample of participants. .3) kg in usual care. Within ethnicity-gender subgroups, changes were consistently smaller in sodium reduction vs usual care for men and consistently larger in sodium reduction vs usual care for women. None of these weight change differences attained statistical significance either in the total sample or in subgroups, and this was also true for the dietary data subsample (Table 4) . We were unable to evaluate changes in overall energy balance because quantitative data on energy expenditure were not collected. However, the smaller weight change in the sodium reduction group is consistent with the significantly larger decrease in kilocalories in this group (Table 4) .
BP changes
Overall treatment effects Some follow-up BP data were obtained for 98% of participants, and 95% attended at least one of the series of three final BP visits at 36 months or later. As shown in Figure 2 , mean BP decreased in both sodium reduction and usual care. The intervention effect on SBP was largest at 6 months (mean (s.d.)
À5.1 (8.6) and À2.2 (8.1) in sodium reduction vs usual care (net change, mean (s.e.) À2.9 (0.5); Po0.001)) but was also statistically significant at 18 months (mean (s.d.) À3.8 (8.1) and À1.8 (7.0) in sodium reduction vs usual care; net change, mean (s.e.)À2.0 (0.5); Po0.001) and 36 months (mean (s.d.)À0.7 (9.0) and þ 0.6 (8.5) in sodium reduction vs usual care (net change, mean (s.e.) À1.2 (0.5); Sodium reduction for hypertension prevention SK Kumanyika et al P ¼ 0.02)). The decrease in DBP was initially larger in sodium reduction, for example, a mean (s.d.) of À4.4 (6.7) at 6 months, compared with À2.8 (6.1) in usual care (net change, mean (s.e.) À1.6 (0.4); Po0.001). The intervention effect on DBP was slightly smaller but also statistically significant at 18 months ((mean (s.d.) À4.4 (6.5) and -3.2 (5.8) in sodium reduction and usual care, respectively (net change, mean (s.e.) À1.2 (0.4); P ¼ 0.002)) but not at 36 months (mean (s.d.) À3.0 (6.5) and À2.4 (7.0) in sodium reduction and usual care, respectively (net change, mean (s.e.) À0.7 (0.4); P ¼ 0.10)). The 18-and 36-month sodium intervention effects on SBP and DBP were relatively unchanged by adjustment for potentially relevant baseline (eg, ethnicity, gender, age, BP, BMI, and sodium excretion) variables: À1.85/À1.18, for the intervention effect on SBP (P ¼ 0.0001) and DBP (P ¼ 0.0029) at 18 months; À1.35/À0.61, for the intervention effect on SBP (P ¼ 0.0165) and DBP (P ¼ 0.16) at 36 months. Life-table probabilities indicated reductions in hypertension incidence in sodium reduction vs usual care participants at two of four time points assessed: relative hazards (95% CI) for developing an end point (as defined in Materials and methods) were 0.61 (0.38, 0.98), P ¼ 0.04; 0.88 (0.70, 1.11), P ¼ 0.28; 0.88 (0.75, 1.02), P ¼ 0.09; and 0.86 (0.74, 0.99), P ¼ 0.04, respectively, at 6, 18, 36, and 48 months. The overall reduction in hypertension incidence associated with the sodium intervention was 18% (relative risk (RR) (95% confidence intervals) from Cox regression analysis ¼ 0.82 (0.68, 1.00), P ¼ 0.048).
Analyses by ethnicity-gender subgroups
The attenuation of the sodium intervention effect on mean SBP and DBP over time observed in the overall data was also observed within ethnicity-gender subgroups (Table 5) . Larger net effects for blacks than whites were suggested in several instances (in men for both SBP and DBP at 6 months and for DBP at 18 months; in women for SBP throughout and for DBP at 18 and 36 months). However, confidence intervals for black men and women were wide. Multivariate analyses (adjusting for the main effects of gender, ethnicity, and baseline BP, weight, and sodium excretion) did not reveal significant interactions for BP effects by ethnicity-gender subgroups at either 18 or 36 months (all interaction P-values 40.05).
For exploratory purposes (Table 6) , ethnicitygender differences in effects on mean BP were further analysed stratifying for AGT genotype within the limitations of small cell sizes for black men and women and the virtual absence of GG homozygotes among blacks, as noted by Hunt et al. 16 In whites, the intervention effect in decreasing BP was largest in the AA subgroup and smallest in the GG subgroup, with the AG group intermediate. Among black women and for DBP among black men the intervention effect was greater in AA than in AG. Life-table analysis in ethnicity-gender subgroups indicated that hypertension incidence was the highest for black women (see Figure 3) . Incidence was lower in sodium reduction than usual care in all the four ethnicity-gender subgroups, but effects were not statistically significant within subgroups. Relative risks (95% confidence intervals) from Cox regression were: white men RR ¼ 0.82 (0.63, 1.07); black men, 1.00 (0; 51, 1.94); white women, 0.89 (0.60, 1.32); black women, RR ¼ 0.61 (0.36, 1.03).
Discussion
As reported previously, 11 the TOHP II sodium reduction intervention was associated with an overall significant advantage in BP control over a 3-4-year period in this large sample of overweight men and women. Adherence to the sodium intervention was incomplete when judged in terms of the stated goal of a mean sodium excretion of 80 mmol/ day, but the amount of sodium reduction achieved was sufficient to result in a statistically significant treatment effect associated with assignment to sodium reduction vs usual care, using either hypertension incidence or SBP as the outcome variable. The impact of sodium reduction on DBP, although apparent at 18 months, was not sustained.
Attribution of effects to sodium reduction
As discussed in an accompanying paper, 13 a gradient of BP change in response to sodium intake change, identified in analyses by quintile of sodium intake change or using linear regression, supports the attribution of the treatment effects to sodium reduction. In addition, other than the observed changes in sodium intake, no other changes that might have explained the significant sodium reduction vs usual care differences in BP were identified. There was no net difference in weight change during follow-up. The net decreases in calcium and vitamin C, observed in the dietary data subsample, would attenuate, not enhance, net differences in BP reduction; however, the differences observed were probably too small even for this effect. For example, 2.5-5 mmol (100-200 mg) less calcium intake might raise SBP by 0.2-0.4 mmHg. 19 The reported reduction in saturated fat was about 33% and might have contributed to the BP decrease. 20 However, with dietary data for only a subsample of participants, we were unable to model directly any possible effects of change in saturated fat intake on BP change.
Goal attainment
The targeted level of sodium excretion was achieved only among the high attenders, and, overall, by only 21% of those assigned to the intervention. The difficulty in reducing sodium intake by more than about one-third within the context of the current US food supply has been well documented. 21 The greatest difficulty is encountered in avoiding sodium that has already been added to processed or catered foods rather than in changing discretionary salting behaviors, [21] [22] [23] and this difficulty will generally be proportional to caloric intake because sodium and calorie levels in food are correlated. Overweight individuals consume more calories as well as sodium compared to the nonoverweight and will, therefore, have more difficulty achieving a targeted lower sodium intake unless their calorie intake is also reduced. For example, the TOHP I participants, who had a baseline BMI of 27 kg/m 2 , had a baseline average sodium excretion of 155 mmol/24 h, 10 whereas the baseline sodium excretion in the TOHP II sodium reduction arm (mean BMI 31 kg/m 2 ) was 188 mmol/24 h. The similar reductions in sodium excretion at 18 months among the intervention participants in these two studies (eg, 55 mmol/24 h in TOHP I and 60 mmol/24 h in TOHP II) resulted in greater goal attainment in TOHP I (99 mmol/24 h in TOHP I) than in TOHP II (125 mmol/24 h).
Gender differences
Both the absolute (60 vs 34 mmol/24 h) and relative (35 vs 25%) reductions from baseline to 36 months among intervention participants were somewhat larger for men, but the absolute levels of attained sodium excretion were nevertheless lower for women (140 vs 121 mmol/24 h for men and women, respectively) because of the men's higher baseline caloric intakes and baseline sodium excretion levels. However, intervention effects on BP did not appear to differ by gender.
Ethnic differences
Sodium reduction lowered BP in all the four race-gender groups studied. Within the limitations of our design, that is, TOHP II was not powered for subgroup analyses by race/ethnicity, we did not observe greater responsiveness to the sodium intervention in the black participants, even with the much higher frequency of the A allele in blacks than whites in this sample. However, the range of sodium intake in this study population was relatively high. A larger effect of sodium reduction in overweight African Americans compared to overweight whites might exist at a lower sodium intake range. Less sodium reduction among black participants has been reported in some studies, 10, 24 possibly attributable to regional or cultural factors, but this has not be observed in other studies. 25, 26 However, no ethnic difference in the attainment of the sodium reduction goal was observed here. It is doubtful that this finding was affected by the somewhat larger proportion of missing urine data in blacks than whites, because the overall proportion of missing data was relatively small.
Systolic vs diastolic blood pressure
The findings suggest a stronger SBP than DBP response to sodium reduction. DBP is inherently more difficult to measure accurately than SBP and a measurement artifact was, therefore, considered. However, a selective error affecting DBP at 36 months but not 18 months seems unlikely, particularly given the rigorous methods used for BP measurement and the masking of observers to treatment assignment. 12 In a separate analysis, we considered the possibility that the end-study DBP was particularly affected by non-study end points, 27 for example, prescription of BP medications by the personal physician, but this did not appear to have occurred.
Smaller effects of sodium reduction on DBP than SBP are reported frequently from clinical trials of sodium reduction [2] [3] [4] [5] 28 with the apparent, although usually implicit, assumption that the expected effect on SBP and DBP is of the same importance, even if not in magnitude. However, this view is contrary to an increasing body of literature both from large cohort studies, especially the approximately 350 000 middle-aged men screened for the Multiple Risk Factor Intervention Trial 29 and from randomized trials focused on systolic hypertension in older persons. [30] [31] [32] The need to emphasize reductions in systolic pressure has attained recognition in clinical guidelines for the treatment of hypertension for middle-aged and older adults. 32 
Public health implications
The ultimate significance of these results is tied to the ability to achieve sodium reduction in a freeliving population. The average decrease in sodium excretion attained in TOHP II was adequate for testing the study hypothesis but was not large in an absolute sense, particularly given the baseline intakes of these overweight persons. Larger sodium reductions were achieved in the DASH-Sodium study 33 by providing participants with prepared foods. The level of sodium reduction in TOHP II approximates the maximum that can be achieved and maintained by individuals making food selections in the community even when these individuals are highly motivated and extensively counseled. 4, 5, [34] [35] [36] Even the relatively modest level of sodium reduction observed in TOHP II is unlikely to be attained in the general US population without changes in the food supply.
Conclusion
These data support the potential public health benefit of sodium reduction for hypertension prevention, but clearly demonstrate that sodium reduction is too difficult for many people to achieve. The reduction in the incidence of hypertension, with parallel reductions in complications and health care costs, that could be achieved through sodium reduction among overweight individuals, might be doubled were a greater degree of sodium reduction made more feasible through the types of food supply changes that have been recommended. 37, 38 These results should not be construed to suggest that overweight individuals with high normal BP opt for sodium reduction 'instead of' reducing their weight or undertaking other potentially beneficial lifestyle changes. Rather, these findings support the inference that sodium reduction has important potential benefits for BP control even without concurrent weight reduction, and are supported by observational data linking sodium reduction to reductions in cardiovascular mortality in overweight individuals. [39] [40] [41] 
